Surface-tailored anti-HER2/neu-solid lipid nanoparticles for site-specific targeting MCF-7 and BT-474 breast cancer cells

• Type: Article in International Scientific Journal
• Date: 2019

Authors

Souto, EB (Author) Other; Doktorovova, S (Author) Other; Campos, JR (Author) Other; Martins Lopes, P (Author) Other; Silva, AM (Author) Other

Journal

Title: European Journal of Pharmaceutical Sciences

Vol. 128

Pages: 27-35

ISSN: 0928-0987

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 31 Citations

Other information

Authenticus ID: P-00Q-2Z0

DOI: 10.1016/j.ejps.2018.11.022

Abstract (EN): CAB51, a compact antibody against human epithelial growth receptor 2 (HER2, ErbB2), has been linked to cationic Solid Lipid Nanoparticles (SLN) via streptavidin-biotin interaction and their targeting potential evaluated against breast cancer cells. The amount of streptavidin and biotinylated antibody was optimised by monitoring the mean complex size (intensity weighed average diameter), polydispersity index and immediate stability in phosphate buffer saline (PBS). The effect on MCF-7 and BT-474 cells was evaluated at concentrations of 0.01 mg/mL and 0.1 mg/mL (counted as solid lipid). Streptavidin adsorption onto SLN surface had no influence on cell viability. Linking the antibody showed a synergistic effect on cell viability at lowest concentration tested (0.01 mg/mL) which was lower than that observed after exposure to SLN alone or antibody alone. At the higher tested concentration (0.1 mg/mL), the observed toxicity was entirely governed by the inherent toxicity of the SLN themselves. Streptavidin adsorption had no effect on accumulation in cells, while the antibody-containing complexes showed clearly increased internalisation in both cell lines. In HER2/neu positive BT-474 higher internalisation was observed than in HER2/neu negative MCF-7.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9